secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0000950170-25-014154
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint DURAVYU Phase 2 VERONA meets primary endpoint in DME; 2.7mg shows +7.1 letter BCVA gain
--------------------------------------------------------------------------------

- DURAVYU 2.7mg met primary endpoint with extended time to first supplemental injection vs aflibercept.
- At week 24, +7.1 letter BCVA gain and 76-micron CST reduction; 73% supplement-free vs 50%.
- Favorable safety: no DURAVYU-related ocular or systemic SAEs, no endophthalmitis or retinal vasculitis.
- Phase 3 non-inferiority pivotal program planned by end of 2025; FDA meeting in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025014154/0000950170-25-014154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025014154/eypt-20250205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-014154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer